Duopharma Biotech Berhad Duopharma Biotech Berhad

Duopharma Biotech Berhad

7148

Rank in Stocks #15495
Duopharma Biotech Berhad, an investment holding firm, is actively engaged in... Duopharma Biotech Berhad, an investment holding firm, is actively engaged in the pharmaceutical sector. Its operations encompass the research, development, manufacturing, distribution, and import of medicinal products, serving markets in Malaysia and internationally. The company's extensive product range includes consumer health items like vitamins, nutritional supplements, pain relievers, eye care solutions, antacids, and skincare products. It also provides generic medications across various therapeutic classes, such as cardiovascular, dermatological, hormonal, respiratory, neurological, musculoskeletal, and anti-infective agents. Furthermore, Duopharma offers specialized pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables, addressing ailments like diabetes, cancer, cardiovascular diseases, and renal disorders. Notable products include vascor, insugen, kytron, and unihepa. Its well-known brands feature Champs, Flavettes, Eye Glo, Proviton, Naturalle, and Uphamol. Beyond its core pharmaceutical activities, the company is also involved in property management and the trading of chemical products. Founded in 1978 and headquartered in Kuala Lumpur, Malaysia, the company adopted its current name, Duopharma Biotech Berhad, in February 2019, having previously been known as CCM Duopharma Biotech Berhad.
Share Price
$0.26961465
Last synced: 2026-11-13
Market Cap
$259.35M
Change (1 day)
0.74%
Change (1 year)
-13.15%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
EPS for Duopharma Biotech Berhad (7148)
EPS as of June 2026 TTM: $0.03
According to Duopharma Biotech Berhad's latest financial reports, its current EPS (TTM) is $0.03. At the end of 2025 the company had an EPS of $0.02, an increase over its 2024 EPS of $0.01.
EPS history for Duopharma Biotech Berhad from 2006 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $0.03 34.50%
2025 $0.02 53.42%
2024 $0.01 22.69%
2023 $0.01 -29.17%
2022 $0.02 -0.59%
2021 $0.02 6.96%
2020 $0.02 4.64%
2019 $0.02 14.39%
2018 $0.01 9.09%
2017 $0.01 75.36%
2016 $0.01 -29.59%
2015 $0.01 -43.35%
2014 $0.02 2.37%
2013 $0.02 15.75%
2012 $0.01 1.39%
2011 $0.01 -10.00%
2010 $0.02 5.26%
2009 $0.02 11.76%
2008 $0.01 -18.07%
2007 $0.02 17.73%
2006 $0.01 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$6.03 22,315.99%
DE
$6.01 22,233.83%
DE
$1.53 5,598.51%
JP
$3.66 13,505.95%
CH
$0.45 1,572.86%
IL

Questions about Duopharma Biotech Berhad's earnings per share (EPS)

What is Duopharma Biotech Berhad's earnings per share (EPS)?

Duopharma Biotech Berhad's earnings per share (EPS) over the last twelve months is $0.03, as of Jun 2026.

What was Duopharma Biotech Berhad's earnings per share (EPS) in 2025?

In 2025, Duopharma Biotech Berhad's earnings per share (EPS) was $0.02, 100.00% more than in 2024 ($0.01).

How has Duopharma Biotech Berhad's earnings per share (EPS) changed since 2020?

From 2020 to 2025, Duopharma Biotech Berhad's earnings per share (EPS) went from $0.02 to $0.02, an average growth of 0.00% a year.

How does Duopharma Biotech Berhad's earnings per share (EPS) compare with similar companies?

Duopharma Biotech Berhad's earnings per share (EPS) ($0.03) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.03.